- Home
- MIRM vs QRVO Comparison
MIRM vs QRVO Comparison
Compare MIRM & QRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | QRVO |
|---|---|---|
| Founded | 2018 | 1957 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 7.9B |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MIRM | QRVO |
|---|---|---|
| Price | $99.83 | $95.78 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 13 |
| Target Price | ★ $119.85 | $90.64 |
| AVG Volume (30 Days) | 700.1K | ★ 1.2M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 74.59 | ★ 524.14 |
| EPS | N/A | ★ 3.62 |
| Revenue | $19,138,000.00 | ★ $3,678,517,000.00 |
| Revenue This Year | $26.22 | $0.81 |
| Revenue Next Year | $22.04 | N/A |
| P/E Ratio | ★ N/A | $26.53 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $63.23 | $75.43 |
| 52 Week High | $130.00 | $109.49 |
Technical Indicators
Market Signals| Indicator | MIRM | QRVO |
|---|---|---|
| Relative Strength Index (RSI) | 40.32 | 56.53 |
| Support Level | $88.08 | $93.91 |
| Resistance Level | $107.51 | $99.08 |
| Average True Range (ATR) | 4.27 | 2.63 |
| MACD | -0.39 | 0.39 |
| Stochastic Oscillator | 44.10 | 72.19 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About QRVO Qorvo Inc.
Qorvo represents the combined entity of RF Micro Devices and TriQuint Semiconductor, which merged in January 2015. The company specializes in radio frequency filters, power amplifiers, and front-end modules used in many of the world's most advanced smartphones. Qorvo also has a suite of products sold into a variety of non-smartphone end markets, such as wireless base stations, cable TV and networking equipment, and infrastructure and military applications.